Federation Des Caisses Desjardins Du Quebec Alnylam Pharmaceuticals, Inc. Transaction History
Federation Des Caisses Desjardins Du Quebec
- $23.7 Billion
- Q3 2025
A detailed history of Federation Des Caisses Desjardins Du Quebec transactions in Alnylam Pharmaceuticals, Inc. stock. As of the latest transaction made, Federation Des Caisses Desjardins Du Quebec holds 14,627 shares of ALNY stock, worth $6.57 Million. This represents 0.03% of its overall portfolio holdings.
Number of Shares
14,627
Previous 7,549
93.76%
Holding current value
$6.57 Million
Previous $2.46 Million
170.99%
% of portfolio
0.03%
Previous 0.01%
Shares
26 transactions
Others Institutions Holding ALNY
# of Institutions
918Shares Held
117MCall Options Held
1.25MPut Options Held
1.49M-
Capital World Investors Los Angeles, CA16.4MShares$7.38 Billion1.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.6MShares$6.09 Billion0.1% of portfolio
-
Black Rock Inc. New York, NY9.55MShares$4.29 Billion0.05% of portfolio
-
Capital Research Global Investors Los Angeles, CA7.22MShares$3.24 Billion0.65% of portfolio
-
Jpmorgan Chase & CO New York, NY4.54MShares$2.04 Billion0.14% of portfolio
About ALNYLAM PHARMACEUTICALS, INC.
- Ticker ALNY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 123,028,000
- Market Cap $55.3B
- Description
- Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system...